Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. uri icon

authors

  • Arabi, Yaseen M
  • Beasley, Richard
  • Berry, Lindsay R
  • Bhimani, Zahra
  • Bonten, Marc J M
  • Bradbury, Charlotte A
  • Brunkhorst, Frank M
  • Buxton, Meredith
  • Buzgau, Adrian
  • Cheng, Allen
  • De Jong, Menno
  • Gordon, Anthony C
  • Detry, Michelle A
  • Duffy, Eamon J
  • Estcourt, Lise J
  • Fitzgerald, Mark
  • Fowler, Rob
  • Timothy Girard, MD, MSCI
  • Goligher, Ewan C
  • Goossens, Herman
  • Haniffa, Rashan
  • Higgins, Alisa M
  • Derde, Lennie P G
  • Hills, Thomas E
  • Horvat, Christopher M
  • Huang, David T
  • King, Andrew J
  • Lamontagne, Francois
  • Lawler, Patrick R
  • Lewis, Roger
  • Linstrum, Kelsey
  • Litton, Edward
  • Lorenzi, Elizabeth
  • Nichol, Alistair D
  • Malakouti, Salim
  • McAuley, Daniel F
  • McGlothlin, Anna
  • Mcguinness, Shay
  • McVerry, Bryan J
  • Montgomery, Stephanie K
  • Morpeth, Susan C
  • Mouncey, Paul R
  • Orr, Katrina
  • Parke, Rachael
  • Murthy, Srinivas
  • Parker, Jane C
  • Patanwala, Asad E
  • Rowan, Kathryn M
  • Santos, Marlene S
  • Saunders, Christina T
  • Seymour, Christopher W
  • Shankar-Hari, Manu
  • Tong, Steven Y C
  • Turgeon, Alexis F
  • Turner, Anne M
  • Beidh, Farah Al
  • Van de Veerdonk, Frank Leo
  • Zarychanski, Ryan
  • Green, Cameron
  • Berry, Scott
  • Marshall, John C
  • McArthur, Colin
  • Angus, Derek C
  • Webb, Steven A
  • Annane, Djillali
  • Swaidan, Lolowa Al
  • Beane, Abi

publication date

  • July 12, 2021